Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "center"

1121 News Found

FDA nod to first treatment for rare genetic brain disorder
Drug Approval | March 12, 2026

FDA nod to first treatment for rare genetic brain disorder

The approval comes after a systematic review of published literature


EnteroBiotix completes enrollment in landmark microbiome trial for stem cell transplant patients
Clinical Trials | March 12, 2026

EnteroBiotix completes enrollment in landmark microbiome trial for stem cell transplant patients

The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation


Kainova reports positive Phase I results for receptor antagonist targeting advanced tumors
Clinical Trials | March 12, 2026

Kainova reports positive Phase I results for receptor antagonist targeting advanced tumors

Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile


Alcon launches Hydrus Microstent in India to transform glaucoma care
News | March 11, 2026

Alcon launches Hydrus Microstent in India to transform glaucoma care

The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes


Cirena licenses breakthrough RNA synthesis technology from CU Boulder
Biotech | March 11, 2026

Cirena licenses breakthrough RNA synthesis technology from CU Boulder

The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands


Neuland to launch commercial peptide facility in Hyderabad as global capacity tightens
News | March 10, 2026

Neuland to launch commercial peptide facility in Hyderabad as global capacity tightens

The first of four planned modules at the new plant is expected to come online by summer 2026


Lilly expands affordable access to diabetes & obesity medicines under new medicare programme
Supply Chain | March 10, 2026

Lilly expands affordable access to diabetes & obesity medicines under new medicare programme

Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans


FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis
Drug Approval | March 10, 2026

FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis

The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials